[Haemophilia A therapy of adults. Actual treatment situation in a haemophilia centre].
In a retrospective study from a single treatment centre (Centre for Haemostaseology Muenster) the current treatment conditions of patients with severe haemophilia A (FVIII:C <1%) at the age of ≥ 16 years are described. Data were extracted from paper based diaries of patients in home treatment (n = 70).


RESULTS
A progressive preference towards prophylactic treatment compared to on demand therapy is observed. On average 2.4 injections per week (mean: 1750 IU FVIII per injection) are used in the prophylactic regimen. The consumption of FVIII concentrates is approximately fivefold increased compared to on demand therapy (average 0.5 injections per week). Meanwhile, recombinant FVIII concentrates have become widely accepted in all age groups, they show a proportion of 60% in the clinical practice of the study population.
Institut für Thrombophilie und Hämostaseologie, Praxis Dr. med. Hartmut Pollmann, Loerstraße 19, 48143 Münster. ith@haemophilie-zentrum.de
B
B
Siegmund
H
H
Richter
H
H
Pollmann
D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000235:genetics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000517:prevention & control; D006782:Hospitals, Special; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D055815:Young Adult
D011994:Recombinant Proteins; D005169:Factor VIII